skip navigation

NCI: DCTD: Biometric Research Branch
NCI logo
Biometric Research Branch


Dr. Mei-Yin Polley

Office Address:
Room 5W638
9609 Medical Center Dr
Rockville, MD 20850

Contact Information:
Tel: (240) 276-6157
Fax: (240) 276-7888
Email:polleymc@mail.nih.gov

PolleyMY photo


Research Interests
Design and analysis clinical trials, biomarkers, assay reliability.

CV (Updated Jan., 2015)

Recent Publications 
As of August 25, 2010

Srinivasan R, Phillips JJ, Vandenberg SR, Polley MY, Bourne G, Au A, Pirzkall A, Cha S, Chang SM, Nelson SJ. Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM. Neuro Oncol, 2010 (In Press).

Essock-Burns E, Lupo JM, Cha S, Polley MY, Butowski NA, Chang SM, Nelson SJ. Assessment of perfusion MRI derived parameters in evaluating and predicting response to anti-angiogenic therapy in patients with newly-diagnosed GBM. Neuro Oncol, 2010 (In Press).

Cloyd JM, Acosta FL Jr, Polley MY, Ames CP. En bloc resection for primary and metastatic tumors of the spine: a systematic review of the literature. Neurosurgery 67(2), 435-445, 2010.

Chang EF, Clark A, Smith JS, Polley MY, Chang SM, Barbaro NM, Parsa AT, McDermott MW, Berger MS. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. J Neurosurg, 2010 (In Press)

Mueller S, Polley MY, Lee B, Kunwar S, Pedain C, Wembacher-Schrö E, Mittermeyer S, Westphal M, Sampson JH, Vogelbaum MA, Croteau D, Chang SM. Effect of iaging and catheter characteristics on clinical outcome for patients in the PRECISE study. J Neurooncol, 2010 (In Press).

Khayal IS, Polley MY, Jalbert L, Elkhaled A, Chang SM, Cha S, Butowski NA, Nelson SJ. Evaluation of diffusion parameters as early biomarkers of disease progression in glioblastoma multiforme. Neuro Oncol 12(9), 908-916, 2010.

Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M. Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Neuro Oncol 12(3), 274-282, 2010.

Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD. Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol 12(6), 608-613, 2010.

Schiffman JD, Hodgson JG, VandenBerg SR, Flaherty P, Polley MY, Yu M, Fisher PG, Rowitch DH, Ford JM, Berger MS, Ji H, Gutmann DH, James CD. Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res 70(2), 512-519, 2010.

McBride SM, Perez DA, Polley MY, Vandenberg SR, Smith JS, Zheng S, Lamborn KR, Wiencke JK, Chang SM, Prados MD, Berger MS, Stokoe D, Haas-Kogan DA. Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival. J Neurooncol 97(1), 33-40, 2010.

Sanai N, Polley MY, Berger MS. Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. J Neurosurg 112(1), 1-9, 2010.

Liu R, Solheim K, Polley MY, Lamborn KR, Page M, Fedoroff A, Rabbitt J, Butowski N, Prados M, Chang SM. Quality of life in low-grade glioma patients receiving temozolomide. Neuro Oncol 11(1), 59-68, 2009.

Polley MY, Cheung YK. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests. Biometrics 64(1), 232-41, 2008.



Please send comments and suggestions to Mail to button brb@brb.nci.nih.gov

last updated: Jan. 29, 2015